TB-Bs1 / Traverse Biotech, Genmab - LARVOL DELTA

ROR2-targeted T-cell engager as a novel therapeutic approach in solid tumor (SITC 2024) - "Now, we now investigate whether our in vivo study will further demonstrate TB-Bs1 has anti-tumor efficacy of ROR2+ tumor cells in our established humanized mouse model. Conclusions This study aims to validate ROR2 as a target in cancer immunotherapy and provide a therapeutic proof-of-concept for T-cell engager therapy in a preclinical humanized mouse model of a ROR2-positive tumor."

IO biomarker • Colon Cancer • Colorectal Cancer • Hematological Malignancies • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Sarcoma • Solid Tumor • ROR2

Traverse Biotech to Present Data on ROR2-Targeted T-Cell Engager at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting (PRNewswire) - "Traverse Biotech...announced that it will present a poster at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting, taking place November 6-10, 2024, in Houston, TX. The presentation will showcase preclinical results on TB-Bs1, Traverse's T-cell engaging product candidate targeting ROR2-positive solid tumors."

Preclinical • Oncology • Solid Tumor